Rethinking Ribociclib: Revisiting Dosing, Duration, and the N0 High-Risk Dilemma in the NATALEE Trial [0.03%]
重新思考瑞博西林：NATALEE试验中重新审视剂量、持续时间和N0高风险难题
Akari Mimura,Akihiko Shimomura,Kenju Ando et al.
Akari Mimura et al.
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer [0.03%]
非小细胞肺癌中DNMT3A突变与PD-(L)1抑制剂疗效的关系
B Ricciuti,S Scalera,X Wang et al.
B Ricciuti et al.
Purpose: Despite significant improvements in overall survival with PD-(L)1 inhibition, most patients with metastatic non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibition (ICI). Growing evidenc...
Health-Related Quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial [0.03%]
比较肿瘤浸润淋巴细胞与伊匹单抗治疗转移性黑色素瘤患者的生命质量：一项随机III期临床试验结果
R M T Ten Ham,M W Rohaan,M Egeler et al.
R M T Ten Ham et al.
Backgroud: To assess health-related quality of life (HRQoL) in patients with metastatic melanoma treated with a tumor infiltrating lymphocyte investigational medicinal product (TIL-IMP) or ipilimumab (IPI) after failure o...
Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases [0.03%]
识别有中枢神经系统转移的EGFR突变型肺癌的基因组特征
J A Wilcox,M Y Jeng,S Tischfield et al.
J A Wilcox et al.
Background: Despite the intracranial efficacy of osimertinib, CNS metastases remain a major cause of morbidity and mortality in EGFR-mutant non-small cell lung cancer (NSCLC). The genomic drivers of CNS dissemination are ...
Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations [0.03%]
基于临床-公共卫生效益的乳腺癌遗传多基因检测：欧洲肿瘤医学学会精准肿瘤学工作组推荐意见
C Turnbull,M I Achatz,J Balmaña et al.
C Turnbull et al.
Background: With widening therapeutic indications, germline genetic testing is offered to an increasing proportion of patients with breast cancer (BC) via mainstream oncology services. However, the gene set tested varies ...
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses [0.03%]
超灵敏循环肿瘤DNA监测及其在局部晚期宫颈癌患者预后评估中的应用：III期CALLA试验分析结果
J Mayadev,J C Vázquez Limón,F J Ramírez Godinez et al.
J Mayadev et al.
Background: After chemoradiotherapy (CRT), 30%-50% of patients with locally advanced cervical cancer (LACC) relapse, highlighting the unmet need for prognostic biomarkers. In the global randomized CALLA trial (NCT03830866...
Reply to Letter to the Editor "Final results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B" by Sahin and Guven [0.03%]
Sahin和Guven关于“PENELOPE-B试验最终结果的信：帕博西尼与安慰剂对比，用于新辅助化疗后HR+/HER2-高危乳腺癌且存在残留病灶患者的治疗”的回复
S Loibl,V Nekljudova,C Denkert
S Loibl
Reply to Letter to the Editor: 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by Y. Liu & C. Zhang [0.03%]
致编辑的信回函：关于刘玉和张聪对“针对 HER2 阳性转移性乳腺癌脑转移患者的 trastuzumab deruxtecan 池化分析”的研究报告的回答
F André,K Tecson,A Egorov
F André
Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer [0.03%]
预测儿童癌症长期幸存者10年心肌病风险的方法
K Petrykey,Y Chen,A Neupane et al.
K Petrykey et al.
Background: Considering the heightened risk of cancer treatment-related cardiomyopathy and cardiac death in long-term survivors of childhood cancer, we aimed to develop and validate a clinically-applicable risk prediction...
Enhanced risk stratification for stage II colorectal cancer using deep learning-based CT classifier and pathological markers to optimize adjuvant therapy decision [0.03%]
基于深度学习的CT分类器和病理标志物用于II期结直肠癌辅助治疗决策的风险分层优化
Y Q Huang,X B Chen,Y F Cui et al.
Y Q Huang et al.
Background: Current risk stratification for stage II colorectal cancer (CRC) has limited accuracy in identifying patients who would benefit from adjuvant chemotherapy, leading to potential over- or under-treatment. We aim...